Vaccine for children: Expert panel recommends nod to SII for phase 2, 3 trials of Covovax

India is probably going to begin trials of one other vaccine, Covovax, on youngsters. The Subject Expert committee (SEC) on Tuesday really useful granting permission to Serum Institute of India for conducting Phase two and three trials of the vaccine on youngsters aged 2 to 17 with sure circumstances.

The trials will cover 920 children, 460 every within the age-group of 12 to 17 and a couple of to 11 throughout 10 websites.

ALSO READ: Covid vaccines for children: Here are the options in India

(*3*) a supply infored information company PTI.


The Pune-based pharmaceutical firm had submitted a revised protocol for inclusion of pediatric cohort within the ongoing Covovax phase 2 and 3 observer-blind, randomised, managed research in Indian adults aged 18 years and above to decide the security and immunogenicity of the jab.

In the revised software submitted final week, SII director (authorities and regulatory affairs) Prakash Kumar Singh and director Dr Prasad Kulkarni acknowledged that globally, all adults aged 18 and above are being vaccinated and after this inhabitants is protected towards Covid-l9, youngsters will stay essentially the most vulnerable group.

ALSO READ: Vaccine boost: Covaxin for children above 2 years by September, says AIIMS chief


“There have been reports of severe disease, including deaths in vulnerable children. It has also been predicted that the third wave of the pandemic may affect children in the country.

“Moreover, till all age teams, together with youngsters are coated underneath vaccination. The SARS-CoV-2 virus could stay in circulation, thus holding everybody in danger of extreme illness,” they said in the letter.


Considering all these factors, several companies have already started evaluating the safety and immunogenicity of COVID-19 vaccines in the pediatric population, the SII has stated.

ALSO READ: Covid-19 vaccine for children likely next month: Health Minister Mansukh Mandaviya

The SII is learnt to have informed that their collaborator, Novavax, Inc., US has already generated a large amount of data in adults in different countries and that the safety, efficacy and immunogenicity data on the Novavax COVID-I9 vaccine are very robust, which includes a safety database of more than 50000 adults with data from Australia, South Africa, UK and USA and preliminary safety data in 2248 children.

“Further within the ongoing Phase 2/3 research in India, greater than 1,400 individuals have acquired a minimum of the primary dose of the vaccine with no security considerations reported thus far,” the application stated.

“This will be certain that a life-saving vaccine will be introduced in on the earliest for our pediatric inhabitants additionally as well as to the grownup inhabitants, instantly after grant of Emergency Use Authorisation. “


“This approval will guarantee an early availability of Covid-19 vaccine for youngsters of our nation in step with our prime minister’s clarion name Atmanirbhar Bharat and can assist in quicker elimination of the Covid-19 pandemic,” Singh mentioned in the application.

On June 30, the company recommended against granting permission to SII for conducting phase 2 and 3 trials of Covovax on children aged between 2 to 17 years, following which the company had submitted a revised study protocol last week.

(With inputs from PTI)

ALSO WATCH: Children could escape third wave of Covid-19 wave: AIIMS research

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.